文献类型：期刊文献

英文题名：Study on the protective effect and mechanism of Dicliptera chinensis (L.) Juss (Acanthaceae) polysaccharide on immune liver injury induced by LPS

作者：Xu, Qiongmei[1];Xu, Jie[1];Zhang, Kefeng[1];Zhong, Mingli[1];Cao, Houkang[2];Wei, Riming[1];Jin, Ling[2];Gao, Ya[1,2]

第一作者：Xu, Qiongmei

通信作者：Gao, Y[1];Jin, L[2]

机构：[1]Guilin Med Univ, Coll Pharm, Guilin 541004, Guangxi, Peoples R China;[2]Gansu Univ Chinese Med, Coll Pharm, Lanzhou 730000, Gansu, Peoples R China

第一机构：Guilin Med Univ, Coll Pharm, Guilin 541004, Guangxi, Peoples R China

通信机构：[1]corresponding author), Guilin Med Univ, Coll Pharm, Guilin 541004, Guangxi, Peoples R China;[2]corresponding author), Gansu Univ Chinese Med, Coll Pharm, Lanzhou 730000, Gansu, Peoples R China.|[1073501e14fb35863569f]甘肃中医药大学药学院（西北中藏药协同创新中心办公室）;[10735]甘肃中医药大学;

年份：2021

卷号：134

外文期刊名：BIOMEDICINE & PHARMACOTHERAPY

收录：;Scopus(收录号：2-s2.0-85098147576);WOS:【SCI-EXPANDED(收录号:WOS:000612228100006)】；

基金：This study was supported by National Natural Science Foundation of China (81960779, 81760114, 81660104, 81860673), National Science Foundation of Guangxi Province of China (2017GXNSFAA198218, 2017GXNSFAA198326 and 2018GXNSFAA281040), and Special funding for 2017 Guangxi BaGui Scholars.

语种：英文

外文关键词：Polysaccharides from Dicliptera chinensis; Immunological liver injury; NF-kappa B; Fas/FasL

摘要：The purpose of this study is to use Dicliptera chinensis (L.) Juss (Acanthaceae) polysaccharide (DCP) to act on the NF-kappa B inflammatory pathway and Fas/FasL ligand system, in order to find a new method to improve immune liver injury. Lipopolysaccharide (LPS) was used to establish an injury model in vivo (Kunming mice) and in vitro (LO2 cells). In this experiment, hematoxylin-eosin (H&E) staining and related biochemical indicators were used to observe the pathological changes of liver tissues, oxidative stress and inflammatory reactions. Immunohistochemistry, ELISA, RT-PCR and Western blot were used to detect protein or mRNA expressions associated with inflammation response and apoptosis. The experimental results show that the model group has obvious liver cell damage and inflammatory infiltration. After DCP intervention, it could significantly reduce the levels of ALT, AST, ALP, TBIL and MDA in serum, and increase the content of SOD and GSH-Px. In addition, DCP can reduce the expression level of NF-kappa B in the liver and reduce the release of downstream inflammatory factors TNF-alpha, IL-6 and IL-1 beta, thereby reducing the inflammation. At the same time, DCP can significantly inhibit the expression of Fas/FasL ligand system and apoptosis related-proteins and mRNA, which in turn can reduce cell apoptosis. In conclusion, DCP can alleviate liver injury by inhibiting liver inflammation and apoptosis, which provides a new strategy for clinical treatment of immune liver injury.